Fabre Ambitions In German Market
French drugmaker Pierre Fabre aims to increase annual sales in Germany to about 50 million Deutschemarks ($32.5 million) as part of a strategy to strengthen its market presence in areas other than southern Europe.
Company director Hubert Olivier, reflecting Fabre's traditional secretiveness, declined to disclose the extent of its existing drugs business in Germany, but said that the established German subsidiary Robapharm GmbH and the Hamburg affiliate have been regrouped under a unified management in Freiburg.
These entities will operate in future under the names of Pierre Fabre Pharma GmbH and Pierre Fabre Dermo Kosmetik GmbH. A company and brand image will be created for the German market. Fabre group sales reached some 1.5 billion marks worldwide last year, with drug sales accounting for 67% of the total and dermatological cosmetics the balance. Expansion will be funded, as before, out of the company's own resources.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze